Heatbud logo
TOP CHARTS
BLOG POSTS
SEARCH
HELP CENTER
LOGIN / SIGNUP
Market ResearchNest Visit zone home page
Open Zone
Favorite
ZONE ACTIONS
< Previous Post
> Next Post
Create a Post
Create a Zone
MY ZONES
Login to favorite zones.
TOP ZONES+
  • Life Long
       
  • Business
       
  • Market ResearchNest
       
  • MarketResearch
       
  • Trendy Women Tops That Will Help You To Improve
       
  • eMarketOrg.com
       
  • Health
       
  • College
       
  • Beauty & Fashion
       
  • My Zone
       
  • AlgoroReports
       
  • Research Trades Business Report
       
  • Fashion Stylist
       
  • Chemical
       
  • Electronics Devices
       
  • Car Accessories
       
  • Seeds & Grasses
       
  • Marketresearchreport.biz
       
  • Politics
       
  • Industry Research Forcast
       
C5a Anaphylatoxin Chemotactic Receptor 1 Therapeutics H2 Pipeline Industry Review 2017
by
Share Blog Post by URL
UNIQUE VIEWS   +   UP VOTES Vote Up   -   DOWN VOTES Vote Down   +   COMMENTS Comments   =   HEAT INDEX What is Heat Index?

MarketResearchNest.com adds “C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 Or C5AR1) - Pipeline Review, H2 2017” new report to its research database. The report spread across in 54 pages with table and figures in it.

 

C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production. The molecules developed by companies in Phase III, Phase I and Preclinical stages are 1, 1 and 4 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Cardiovascular, Gastrointestinal, Genito Urinary System And Sex Hormones, Infectious Disease, Mouth and Dental Disorders, Oncology and Respiratory which include indications Alzheimer's Disease, Acute Pain, Allergic Asthma, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Atypical Hemolytic Uremic Syndrome (Nondiarrhea- Associated Hemolytic Uremic Syndrome), Chronic Pain, Churg-Strauss Syndrome, Glomerulonephritis, Granulomatosis with Polyangiitis (Wegener Polyangiitis), Huntington Disease, Inflammatory Pain, Kidney Disease, Lung Cancer, Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Microscopic Polyangiitis (MPA), Neuropathic Pain, Periodontitis and Rheumatoid Arthritis. 

Furthermore, this report also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.             

Browse full table of contents and data tables at

https://www.marketresearchnest.com/c5a-anaphylatoxin-chemotactic-receptor-1-cd88-or-c5ar1---pipeline-review-h2-2017.html

Featured News & Press Releases
Jun 06, 2017: Oral Presentation at ERA-EDTA Congress Highlighst Fourth Potential Indication for Avacopan 38
May 23, 2017: ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy 38
Mar 22, 2017: ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy 39
Jan 09, 2017: ChemoCentryx Provides Update on Lead Program Avacopan 39
Nov 07, 2016: ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials (‘CLEAR' and ‘CLASSIC') of Orally Administered Complement 5a Receptor Inhibitor CCX168 (‘Avacopan') 41
Oct 27, 2016: ChemoCentryx Reports Improvement in Renal Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory C3 Glomerulopathy 42
Oct 17, 2016: ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016 42
Jul 13, 2016: UNMC Researcher Secures $2.25 Million Grant to Fight Antibiotic Resistance 44
Jun 16, 2016: ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development 44
Jun 01, 2016: ChemoCentryx Receives European Medicines Agency Priority Medicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis 46
May 23, 2016: ChemoCentryx Announces Presentation of Positive Results from Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 at the 53rd ERA-EDTA Congress 47
Apr 28, 2016: ChemoCentryx Receives FDA Orphan Products Development Grant for Orally Administered Complement 5a Receptor Inhibitor CCX168 for Treatment of ANCA-Associated Vasculitis 49
Jan 06, 2016: ChemoCentryx Announces Positive Results in Phase II ANCA-Associated Vasculitis CLEAR Trial of Orally Administered Complement 5a Receptor Inhibitor CCX168 49
Nov 05, 2015: ChemoCentryx Presents Phase II Results on CCX168 at the American Society of Nephrology Annual Meeting 50
Aug 19, 2015: UNMC spinoff company to test H1N1 vaccine in animal trial 51

Companies mentioned in this report includes:

AFFiRiS AG,ChemoCentryx Inc,Dompe Farmaceutici SpA,Novo Nordisk A/S,Prommune Inc

 

Order a Premium Report Copy at https://www.marketresearchnest.com/purchase.php?reportid=253138

 

Scope
- The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
- The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RandD brief, licensing and collaboration details and other developmental activities 
- The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects 
- The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics


Reasons to buy:
- Gain strategically significant competitor information, analysis, and insights to formulate effective RandD strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 

Enquiry before buying at https://www.marketresearchnest.com/enquirybuy.php?reportid=253138  

               

About Us:                           

MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.

                                                   

Contact Us

Mr. Jeet Jain

Sales Manager

sales@marketresearchnest.com

+1-240-284-8070

Connect with us:  Google+ | LinkedIn | Twitter | Facebook

Comments:
0 blogger(s) are following this post, but not you. Follow?
No comments yet.
 
Post a Comment:

 
Related Posts: